<i>In silico</i>and<i>in vitro</i>evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimizationPiotr J. Kamola, Joel D. Parry, Kitty Moores et al.|Nucleic Acids Research|2015Cited by 109
Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense DrugsPiotr J. Kamola, Joel D. Parry, Klio Maratou et al.|Molecular Therapy — Nucleic Acids|2017Cited by 62
Octimibate, a potent non‐prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptorJanet E. Merritt, T J Rink, Trevor J. Hallam et al.|British Journal of Pharmacology|1991Cited by 45
Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic FibrosisKenneth L. Clark, Mark R. Edbrooke, Stephen Hughes et al.|Molecular Therapy — Nucleic Acids|2013Cited by 37